TrumpRx, FTC Action & the Next Era of PBM Transparency

Corporate Synergies, a Foundation Risk Partners Company

Will Greater PBM Transparency Lower Drug Costs?

The pharmacy landscape is evolving rapidly as policymakers, regulators and employers intensify scrutiny of prescription drug pricing and pharmacy benefit manager (PBM) practices. In this session, Tim Sullivan, pharmacist and VP, Integrated Medical & Pharmacy Growth with UnitedHealthcare, explores whether recent reforms, including the Trump Administration’s drug pricing initiatives, TrumpRx, FTC enforcement actions and emerging PBM transparency requirements, will fundamentally reshape the pharmaceutical supply chain or simply create new layers of complexity.

Attendees will gain insight into the latest federal developments, including PBM compensation disclosure proposals, rebate reform efforts, direct to consumer drug purchasing models and heightened plan sponsor oversight responsibilities. The session will examine the practical implications for employer health plans, PBM contracting strategies, fiduciary risk, drug affordability and the future of pharmacy benefits.

More Information, How to Register